Company: SMNR
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001193125-25-306962
Chunk: 12

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 12
---
us, of up to 46,250,000 shares of Common Stock issuable to the Selling Stockholders pursuant to awards and obligations
assumed and/or granted under the Plan. Following the completion of the Business Combination, no further awards will be granted under the Plan, however the Plan will continue to govern the outstanding stock option awards granted thereunder.
Subject to the satisfaction of any conditions to vesting of the shares of Common Stock offered hereby (or the exercise of the applicable stock options) pursuant to the terms of the relevant award agreements, the Selling Stockholders may from time to
time sell, transfer or otherwise dispose of any or all of the shares of Common Stock covered by this Reoffer Prospectus through underwriters or dealers, directly to purchasers (or a single purchaser) or through broker-dealers or agents. We will not
receive any of the proceeds from the sale of the shares of Common Stock by the Selling Stockholders. The Selling Stockholders will bear all sales commissions and similar expenses in connection with this offering. We will bear all expenses of
registration incurred in connection with this offering, as well as any other expenses incurred by us in connection with the registration and offering that are not borne by the Selling Stockholders.

6

RISK FACTORS

Investing in shares of our Common Stock involves a high degree of risk. Investors should carefully consider the risks we have described under
the heading “Risk Factors” starting on page 9 in our final prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act on August 13, 2025, in connection with our registration statement on Form S-4 (File No. 333-283019), together with all the other information appearing in or incorporated by reference into this Reoffer Prospectus, before deciding to invest in
our Common Stock. If any of the events or developments we have described occur, our business, financial condition, or results of operations could be materially or adversely affected. As a result, the market price of our Common Stock could decline,
and investors could lose all or part of their investment. The risks and uncertainties we have described are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also impair our business operations. The risks we have described also include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements. See
“Cautionary Note Regarding Forward-Looking Statements.”

DETERMINATION